The RASolute 302 phase 3 randomized trial (n=168 post-chemotherapy patients with RAS-mutant tumors, 92% pancreatic) reported median overall survival of 13 months versus 6 months with standard care, equating to a 60% reduction in death risk. This RCT design provides higher evidence quality than prior observational series, yet the 168-patient relapsed cohort remains modest for a disease where median survival has stagnated near 6-8 months for decades. Manufacturer Revolution Medicines funded and led the study, introducing clear conflicts of interest typical of industry-sponsored oncology trials; independent replication is essential. The source understates incomplete toxicity data (96% adverse events at 300 mg) and omits long-term quality-of-life or resistance mechanisms. Parallel KRAS G12C inhibitor trials, such as the CodeBreaK 100 study (NEJM 2021, n=38 pancreatic subset, objective response 21%), showed shorter progression-free intervals, positioning daraxonrasib's broader RAS(ON) coverage as a mechanistic advance. A 2023 Lancet Oncology meta-analysis of 12,000 pancreatic cases further contextualizes the leap: any therapy exceeding 12 months OS in second-line settings has historically failed confirmatory studies. Missing from coverage is the absence of biomarker-stratified outcomes beyond G12 and the need for head-to-head data against emerging standards like NALIRIFOX.